Tags

Type your tag names separated by a space and hit enter

Risedronate improves bone mineral density in Crohn's disease: a two year randomized controlled clinical trial.
J Crohns Colitis. 2012 Aug; 6(7):777-86.JC

Abstract

BACKGROUND

Patients with Crohn's disease have an increased frequency of osteopenia and osteoporosis. This randomized, controlled, double-blind study assessed the efficacy of risedronate versus placebo in treating low bone mineral density (BMD) in patients with Crohn's disease.

METHODS

88 Crohn's disease outpatients with BMD T-score<-1.0 by dual-energy X-ray absorptiometry were randomly assigned to one of two treatment groups for the two year study duration: one group received risedronate 35 mg weekly while another received placebo. Both groups received daily calcium (Ca; 500 mg) and vitamin D (D; 400 IU) supplementation. Percent change in BMD relative to baseline was compared between the two therapies at 12 and 24 months.

RESULTS

Using intent-to-treat analysis, at 12 months, risedronate+Ca+D increased BMD, relative to baseline, more than placebo+Ca+D in the femoral trochanter (1.4±3.4% vs -0.1±3.1%; p=0.03) and total hip (1.1±2.7% vs -0.1±2.5%;p=0.04). This trend in greater BMD continued for the 24 month duration of the study. There was no difference between the two treatment groups for changes in spine BMD. Subgroup analysis revealed that risedronate+Ca+D resulted in significantly better improvement in femoral trochanter BMD in non-smokers (p=0.01), males (p=0.01), those with a history of corticosteroid use in the preceding year (p=0.01), and current users of immunosuppressants (p=0.04).

CONCLUSIONS

Risedronate, in addition to daily calcium and vitamin D supplementation, is superior to calcium and vitamin D alone in improving femoral trochanter and total hip BMD in patients with Crohn's disease.

Authors+Show Affiliations

Division of Gastroenterology, University of Alberta, Edmonton, Alberta, Canada.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22398088

Citation

Soo, Isaac, et al. "Risedronate Improves Bone Mineral Density in Crohn's Disease: a Two Year Randomized Controlled Clinical Trial." Journal of Crohn's & Colitis, vol. 6, no. 7, 2012, pp. 777-86.
Soo I, Siffledeen J, Siminoski K, et al. Risedronate improves bone mineral density in Crohn's disease: a two year randomized controlled clinical trial. J Crohns Colitis. 2012;6(7):777-86.
Soo, I., Siffledeen, J., Siminoski, K., McQueen, B., & Fedorak, R. N. (2012). Risedronate improves bone mineral density in Crohn's disease: a two year randomized controlled clinical trial. Journal of Crohn's & Colitis, 6(7), 777-86. https://doi.org/10.1016/j.crohns.2012.01.004
Soo I, et al. Risedronate Improves Bone Mineral Density in Crohn's Disease: a Two Year Randomized Controlled Clinical Trial. J Crohns Colitis. 2012;6(7):777-86. PubMed PMID: 22398088.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Risedronate improves bone mineral density in Crohn's disease: a two year randomized controlled clinical trial. AU - Soo,Isaac, AU - Siffledeen,Jesse, AU - Siminoski,Kerry, AU - McQueen,Bob, AU - Fedorak,Richard N, Y1 - 2012/02/10/ PY - 2011/10/04/received PY - 2012/01/04/revised PY - 2012/01/04/accepted PY - 2012/3/9/entrez PY - 2012/3/9/pubmed PY - 2013/1/16/medline SP - 777 EP - 86 JF - Journal of Crohn's & colitis JO - J Crohns Colitis VL - 6 IS - 7 N2 - BACKGROUND: Patients with Crohn's disease have an increased frequency of osteopenia and osteoporosis. This randomized, controlled, double-blind study assessed the efficacy of risedronate versus placebo in treating low bone mineral density (BMD) in patients with Crohn's disease. METHODS: 88 Crohn's disease outpatients with BMD T-score<-1.0 by dual-energy X-ray absorptiometry were randomly assigned to one of two treatment groups for the two year study duration: one group received risedronate 35 mg weekly while another received placebo. Both groups received daily calcium (Ca; 500 mg) and vitamin D (D; 400 IU) supplementation. Percent change in BMD relative to baseline was compared between the two therapies at 12 and 24 months. RESULTS: Using intent-to-treat analysis, at 12 months, risedronate+Ca+D increased BMD, relative to baseline, more than placebo+Ca+D in the femoral trochanter (1.4±3.4% vs -0.1±3.1%; p=0.03) and total hip (1.1±2.7% vs -0.1±2.5%;p=0.04). This trend in greater BMD continued for the 24 month duration of the study. There was no difference between the two treatment groups for changes in spine BMD. Subgroup analysis revealed that risedronate+Ca+D resulted in significantly better improvement in femoral trochanter BMD in non-smokers (p=0.01), males (p=0.01), those with a history of corticosteroid use in the preceding year (p=0.01), and current users of immunosuppressants (p=0.04). CONCLUSIONS: Risedronate, in addition to daily calcium and vitamin D supplementation, is superior to calcium and vitamin D alone in improving femoral trochanter and total hip BMD in patients with Crohn's disease. SN - 1876-4479 UR - https://www.unboundmedicine.com/medline/citation/22398088/Risedronate_improves_bone_mineral_density_in_Crohn's_disease:_a_two_year_randomized_controlled_clinical_trial_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1873-9946(12)00008-6 DB - PRIME DP - Unbound Medicine ER -